Prospective single-center study of chronic myeloid leukemia in chronic phase: Switching from branded imatinib to a copy drug and back

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2830-2834

  Alwan, Alaa Fadhil ^a   Matti, Bassam F ^b   Naji, Aladdin S ^b   Muhammed, Abdulsalam H ^a   Abdulsahib, Manal A ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b BAGHDAD TEACHING HOSPITAL   (Iraq)

Author keywords

Chronic myeloid leukemia; Complete hematologic response; Copy drug; Glivec Gleevec; Imatib; Imatinib

Indexed keywords

IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE PAIN; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HUMAN; IRAQ; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; PROSPECTIVE STUDY; RETREATMENT; SIDE EFFECT; TREATMENT RESPONSE; DISEASE COURSE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE PROGRESSION; DRUG SUBSTITUTION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911419543     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.904508     Document Type: Article

References (25)

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia:2012 update on diagnosis, monitoring, and management. Am J Hematol 2012; 87: 1037-1045.
2. Druker BJ, Talpaz M, Resta DJ, et al. efficacy and safety of a Specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a Specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
4. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2013.
5. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
6. Ghadyalpatil N, Banawali S, Kurkure P, et al. efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: results from a tertiary care referral center in India. J Clin Oncol 2009;27(15 Suppl.): Abstract 10047.
7. Razmkhah F, Razavi M, Zaker F, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med 2010;41:547-550.
8. Gogtay J, Chahchad S, Jadhav S, et al. Response to the case report by Mattar: generic imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol 2010; 92: 772-773.
9. Choufai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010; 3: 272-276.
10. Goubran HA. Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Rep 2009;3:1-3.
11. Asfour IA, Elshazly SA. Changing therapy from Glivec to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009;2:9342.
12. Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010;91:104-106.
13. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
14. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423-1432.
15. Torres A, Navarro JR, Untama J, et al. 5 year experience in chronic phase-chronic myeloid leukemia treated with imatinib copy drugs in a Peruvian hospital. Blood 2011;118(Suppl. 1): Abstract 4449.
16. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981-1987.
17. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
18. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
19. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203.
20. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
21. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2014.
22. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; June 2013.
23. Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013; 122(Suppl. 1): Abstract 92.
24. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifcation. Science 2001;293:876-880.
25. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-677.